Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

31.68

-0.14 (0.44%)

as of Jul 15, 2026, 6:03:36 pm Market Open.

69 watching

Investor Insights

Jul 15, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) is experiencing a significant turnaround under its current CEO, with a remarkable 264% increase since January 2023. The demand for GLP (glucagon-like peptides) remains strong; however, the entry of more generics into the market could lead to declining prices. While analysts highlight the potential for innovation, concerns remain about Teva's lack of innovative capabilities. The stock has shown strong momentum, breaking out over $21 in September and maintaining positive accumulation trends for the past six months. Despite not offering dividends, analysts have set a price target of $34.50 for the stock, indicating further potential growth amidst favorable market conditions for drug stocks.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer,PFE

BUY

Pharmaceutical sector did very poorly over the last 2 years, but deceleration in revenue growth has slowed and profitability has started to improve. Look for the strongest perfoming stock in the sector. As Eli Lilly (LLY-N) is performing better, that would be the better of the 2, but would suggest you look at Sanofi-Aventis (SNY-N) which is close to new highs and Teva Pharmaceuticals (TEVA-Q) in generics.

Wealthica Track your Stocks in your Watch List

DON'T BUY

Prefers others.

BUY

One of the world's largest genetic drug manufactor company. The stock has dropped in the last few weeks. This is a good opportunity to buy stocks.

TOP PICK

Wonderful company. Not overvalued.

BUY ON WEAKNESS

Generic drugs is a great sector. This one is the leader. Accumulate on a gradual basis.

HOLD

Generic drug space is a good place to be. A little high now.

TOP PICK

Generic drugs have done very well. Have increased their margins regularily. Steadily moving up.

BUY

Good growth trend. Good products. May drop in the near term.

TOP PICK

Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Aug 23. Up 1%) Still likes. Likess the generic sector in drugs.

TOP PICK

Stable revenue stream and earnings record. Likes the generic drug sector.

PAST TOP PICK

(Was a top pick on Mar 15. Up 19%.) Still likes.

PAST TOP PICK

(Was a top pick on June 21. Up 7.1%) Good long term story.

TOP PICK

Over 50 new drugs waiting approval. Cheap.

TOP PICK

Global. Good acquisitions. Because it is based in Israel, price has dropped inordinately.

Showing 256 to 270 of 276 entries

Most Recent Experts

Colin Cieszynski

SIA Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)